Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab

Zubir S. Rentiya^Δ1; Daniel A. Ferraz^Δ1,2,3,4; Robert Hutnik⁵; Junun Bae^1,6; Cleide G. Machado²; Cristina Mucciolli³; Augusto Alves L. da Motta²; Lucas Z. Ribeiro³; Zeyu Guan⁴; Rony Carlos Preti²; Walter Y. Takahashi²

DOI: 10.5935/0004-2749.20220006

1. Johns Hopkins University School of Medicine, Department of Radiology, Neurology, Ophthalmology, Baltimore, MD, USA
2. Division of Ophthalmology, University of São Paulo, São Paulo, SP, Brazil
3. Division of Ophthalmology, Federal University of São Paulo, São Paulo, SP,Brazil
4. Moorfield’s Eye Hospital, London, UK
5. Stony Brook Medicine, Department of Surgery, Stony Brook, NY, USA
6. Lake Erie College of Osteopathic Medicine, Erie, PA, USA

Corresponding author

Daniel A. Ferraz
E-mail: [email protected]

Funding: This study received no specific financial support

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose

Print PDF English

How to cite this article:

Rentiya ZS, Ferraz^{Δ1 DA, 2 , 3 , 4} , Hutnik R, et al. Avaliação da sensibilidade ao contraste em retinopatia diabética proliferativa de não alto risco tratada com panfotocoagulação retiniana com ou sem injeções intravítrea de ranibizumabe. Arq. Bras. Oftalmol. 2022;85(1):. 10.5935/0004-2749.20220006

Export citation